Alto Neuroscience (ANRO) Net Equity Issued and Repurchased (2023)
Alto Neuroscience (ANRO) reported Net Equity Issued and Repurchased of $45.0 million for Q4 2023, up 80.0% sequentially from $25.0 million in Q1 2023.
Alto Neuroscience (ANRO) Net Equity Issued and Repurchased (2023) Analysis & Trends
Alto Neuroscience (ANRO) has 1 years of Net Equity Issued and Repurchased data on file, last reported at $45.0 million in Q4 2023.
- For the quarter ending Q4 2023, Net Equity Issued and Repurchased changed N/A year-over-year to $45.0 million; the trailing twelve-month figure through Sep 2024 stood at $45.0 million (changed N/A YoY), and the FY2023 full-year result was $70.0 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased improved to $45.0 million in Q4 2023, from $25.0 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $45.0 million in Q4 2023 to a low of $25.0 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 141.90 Mn |
| 10 | Alto Neuroscience | 869.36 Mn | 869.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 45.00 Mn |
| Dec 31, 2023 | 45.00 Mn |
| Mar 31, 2023 | 25.00 Mn |
| Mar 31, 2023 | 25.00 Mn |